$PTX: Announced last night that distribution of TR
Post# of 22755
(sumatriptan and naproxen sodium) 10/60 mg to wholesalers has begun. TREXIMET
10/60 mg is indicated for use in pediatric patients 12 years of age and older
for the acute treatment of migraine with or without aura.¹ TREXIMET received
U.S. Food and Drug Administration ( FDA ) approval for use in the pediatric
population 12 years of age and older in May 2015 ; however, this formulation just
recently became available due to manufacturing delays. The Company expects to
begin focused product promotion activities in early Q4 2016.
Read More: http://investorshangout.com/post/view?id=4084...z4LduRgRfF